Precision BioSciences, Inc. (DTIL)

$1.675

+0.02 (+1.52%)
Rating:
Recommendation:
-
Symbol DTIL
Price $1.675
Beta 1.699
Volume Avg. 3.20M
Market Cap 185.620M
Shares () -
52 Week Range 1.11-14.38
1y Target Est -
DCF Unlevered DTIL DCF ->
DCF Levered DTIL LDCF ->
ROE -101.59% Strong Sell
ROA -31.22% Strong Sell
Operating Margin -
Debt / Equity 188.44% Buy
P/E -
P/B 1.10 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest DTIL news


Mr. Matthew Kane
Healthcare
Biotechnology
NASDAQ Global Select

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.